KALY and GNBT Could Give GWPH Run For Money In 2019 - See Motley Fool Prediction
December 24 2018 - 9:32AM
InvestorsHub NewsWire
New York, NY -- December 24, 2018 -- InvestorsHub NewsWire --
via nextbigticker.com -- Kali,
Inc. (dba/Kali-Extracts) (USOTC:
KALY) and Generex Biotechnology Corp (OTCQB:
GNBT) through a deal announced between GNBT and US Cannabis
Health, a Joint Venture partnership between KALY and Puration, Inc.
(USOTC:
PURA) and Nouveau Life Pharmaceuticals (USOTC: NOUV) could
potentially soon introduce a cannabis drug that not only rivals GW
Pharmaceuticals’ (NASDAQ: GWPH) Epidiolex, KALY and GNBT’s cannabis
drug development could reveal that GWPH’s Epidiolex infringes on
GNBT patents.
"I believe the underlying value of Kali-Extracts cannabis
biotechnology properties are as of yet unrecognized by the market,"
said Frederick Ferri, CEO of Kali-Extracts. "Doctors involved
in research with our extracts have given me feedback that our
extracts are superior to those of GW Pharmaceuticals [GW
Pharmaceuticals, plc (GWPH)]. As just one
example of what our cannabis biotechnology can lead to, I believe
our developing COPD therapies in combination with the potential for
us to harness the patented RapidMist buccal cavity drug
administration technology of Generex [Generex Biotechnology, Corp.
(GNBT)] through our US Cannabis
Health partnership, would put Kali-Extracts in front of any
cannabis biotechnology company on the market. For that
matter, I think Generex applying its patented RapidMist buccal
cavity administration technology would bode well for Generex as
well. I also happen to think that the combination of our COPD
technology with the RapidMist technology of Generex would
illustrate that GW Pharmaceuticals buccal drug administration is
likely an infringement on Generex's RapidMist patent. In summary,
the market has a lot yet to learn about Kali-extracts cannabis
biotechnology. I hope the COPD example herein begins to give
a glimpse of that yet to be realized value. Finally, I think
the developing partnership between KALY and its other US Cannabis
Health partners with Generex can put KALY, its other US Cannabis
Health partners and Generex on top of their respective markets."
(source - yahoo.com)
KALY and GNBT could impact Motley Fool’s 2019 prediction for
GWPH. See Motley Fool’s prediction #4 of 7 for cannabis stocks in
2019:
4. First U.S. plant-based cannabinoid drug is a big hit,
Big Pharma execs injure themselves after slapping foreheads in
regret
Despite some nattering negativism by skeptics, GW
Pharmaceuticals' (NASDAQ: GWPH) Epidiolex, the
first plant-based cannabinoid drug approved in the U.S., becomes a
smashing commercial success. Even pessimistic analysts project that
Epidiolex likely will become a blockbuster within a few years.
As Epidiolex sales steadily increase, several renowned Big
Pharma executives are forced to receive medical care for injuries
received from slapping themselves on the foreheads in regret. These
slaps stem from the executives reading the histories of their
companies marketing cannabis-based drugs in the early 20th century.
(Source: Motley Fool)
Keep an eye on KALY and GNBT. Both are showing characteristics
of entry level prices you might regret missing.
Learn more about Kali, Inc. at www.kali-extracts.com.
Learn more about Generex at www.generex.com.
Disclaimer:
NextBigTicker.com
(NBT)is a third party publisher and news dissemination service
provider. NBT is NOT affiliated in any manner with any company
mentioned herein. NBT is news dissemination solutions provider and
are NOT a registered broker/dealer/analyst/adviser, holds no
investment licenses and may NOT sell, offer to sell or offer to buy
any security. NBT's market updates, news alerts and corporate
profiles are NOT a solicitation or recommendation to buy, sell or
hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted
as research material. All readers are strongly urged to perform
research and due diligence on their own and consult a licensed
financial professional before considering any level of investing in
stocks. All material included herein is republished content
and details which were previously disseminated by the companies
mentioned in this release or opinion of the writer. NBT is not
liable for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. NBT has not been
compensated for this release and HOLDS NO SHARES OF ANY
COMPANY NAMED IN THIS RELEASE.
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur.
Source: www.nextbigticker.com
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Sep 2023 to Sep 2024